NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
Updated: Jun 13, 2022
RRMM
Relapsed and Refractory Multiple Myeloma
NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma. Patients must have received prior treatment with bortezomib and either thalidomide or lenalidomide and be refractory to their last treatment.
Sponsor
Amgen
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT00511238
Official Title: An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
First Posted : August 3, 2007
Click here to see details on clinicaltrials.gov
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
Blood; 2012 Oct
Drug: carfilzomib
- Arizona: Mayo Clinic Arizona
- California: City of Hope Duarte
- California: University of California San Francisco
- Florida: Moffitt Cancer Center Tampa
- Georgia: Emory University Atlanta
- Illinois: Rush University Medical Center Chicago
- Minnesota: Mayo Clinic Rochester Minnesota
- Missouri: Washington University School of Medicine Saint Louis
- New Jersey: Hackensack University Medical Center
- New York: Roswell Park Cancer Institute Buffalo
- North Carolina: Wake Forest Baptist Health Winston-Salem
- Pennsylvania: University of Pennsylvania Philadelphia
- Tennessee: Sarah Cannon Research Institute Nashville
- Texas: The University of Texas MD Anderson Cancer Center Houston
Locations
United States, Alabama
United States, Arizona
United States, California
United States, Florida
United States, Georgia
United States, Illinois
United States, Kentucky
United States, Michigan
United States, Minnesota
United States, Missouri
United States, New Jersey
United States, New York
United States, North Carolina
United States, Ohio
United States, Pennsylvania
United States, Tennessee
United States, Texas
United States, Utah
Canada, Alberta
Canada, British Columbia
Canada, Ontario
Canada, Quebec